Management of Type 2 Diabetes and Chronic Kidney Disease
Introduction to Finerenone
- Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated for patients with type 2 diabetes and chronic kidney disease with albuminuria, acting by blocking mineralocorticoid receptors to reduce inflammation and fibrosis in the kidneys, without directly affecting glucose metabolism like insulin, sulfonylureas, or SGLT2 inhibitors 1
Safety Profile of Finerenone
- Finerenone does not carry warnings about increased risk of diabetic ketoacidosis (DKA), as it works through the mineralocorticoid receptor pathway and does not affect ketone metabolism, with clinical trials not reporting increased risk of DKA 1
- Finerenone can be safely used in patients with a history of pancreatitis, as there is no evidence suggesting it increases pancreatitis risk, unlike incretin-based therapies which have documented associations with pancreatitis risk 1
- Patients with diabetes are at approximately twofold higher risk of developing acute pancreatitis 2, 3
- Conversely, diabetes develops in approximately one-third of individuals after an episode of acute pancreatitis 2
Medications Associated with Pancreatitis Risk
- Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) should be avoided in patients with pancreatitis due to their association with increased risk of pancreatitis, with a recommended avoidance by the American Diabetes Association 4
- Medications associated with pancreatitis risk include:
The following table summarizes medications associated with gastrointestinal adverse events, including pancreatitis:
Medication Pancreatitis Risk Acitretin Rare cases of fatal fulminant pancreatitis Eluxadoline 5 reported cases in clinical trials Sitagliptin 0.1-0.3% GLP-1 receptor agonists Increased risk
Monitoring and Management of Finerenone
- The American Diabetes Association recommends monitoring serum potassium levels as finerenone can cause hyperkalemia, with initial potassium levels to be ≤4.8 mEq/L before starting treatment, and rechecked 4 weeks after initiation and with dose adjustments 1
- Patients with a history of DKA should continue standard monitoring for recurrent DKA risk factors, with no dose adjustment needed specifically for history of these conditions 1
- The recommended starting dose of finerenone is 10 mg once daily if eGFR 25-60 mL/min/1.73m², and 20 mg once daily if eGFR ≥60 mL/min/1.73m², with dose adjustments based on potassium levels and tolerability 1
Comparison with Other Medications
- Finerenone has a different mechanism of action compared to SGLT2 inhibitors, which carry warnings about increased risk of DKA, making finerenone a safer option for patients with a history of DKA 12
- Benzonatate is a non-narcotic antitussive medication that can be safely used in patients with pancreatitis and diabetes, with no known contraindications or interactions specific to these conditions, as supported by the American Diabetes Association 4
- Oxcarbazepine may represent a safer choice for patients with existing pancreatitis risk factors compared to other anticonvulsants like valproate 6, 11, 13